

# Exploring Diagnostic Pathways and Factors for Early Detection of Lung Cancer in Small and Large Nodule Patients

Yu-Ting Chi <sup>1</sup>, Penglin Lin <sup>1</sup>, Minkyung Shin <sup>2</sup>

<sup>1</sup> Intuitive Surgical Taiwan, Taipei, Taiwan. <sup>2</sup> Intuitive Surgical Korea, Seoul, South Korea. Contact information: Cindy.Chi@intusurg.com; Minkyung.Shin@intusurg.com

## OBJECTIVE

- Lung cancer is frequently diagnosed at advanced stages.
- Early detection significantly improves outcomes.
- This study investigates the characteristics and diagnostic pathways of patients with small nodules (SN) versus large nodules (LN) to identify factors that could improve early diagnosis.

## METHODS

- A retrospective analysis was conducted using the Japanese Medical Data Vision (MDV) from 2008 to 2023.
- Patients with T1a or T1b lung cancer were classified as SN, while those with more advanced T stages were categorized as LN.
- Patients without any diagnostic procedures before cancer confirmation, those with TX, T0, or Tis stages, and those with incomplete records were excluded.
- Patient characteristics, biopsy and imaging rate, and time to cancer confirmation were compared between SN and LN groups.
- Logistic regression was used to identified factors influencing biopsy decisions.

## RESULTS

- The cohort included 11,989 SN and 31,278 LN patients. Only 20.2% of SN and 20.7% of LN patients received biopsy.
- SN patients were younger, more likely to be female, less likely to smoke, and had higher obesity rates.

Table1. Patients baseline characteristics

Characteristics	Small Nodule* (n = 11989)	T1c-T4 (n = 31278)	p-value	ASMD
Sex			<0.001	
Female (n, %)	4739 (39.53%)	8992 (28.75%)		0.023
Male (n, %)	7250 (60.47%)	22286 (71.25%)		0.023
Age (mean, SD)	70.97 (9.64)	73.59 (10.13)	<0.001	0.265
BMI *			<0.001	
Normal (n, %)	8032 (66.99%)	19836 (63.42%)		0.075
Obese (n, %)	2748 (22.92%)	4898 (15.66%)		0.185
Underweight (n, %)	1209 (10.08%)	6544 (20.92%)		0.303
Smoking index			<0.001	
Nonsmoker (n, %)	4765 (39.74%)	9585 (30.64%)		0.191
<400 (n, %)	1123 (9.37%)	2293 (7.33%)		0.074
400~799 (n, %)	1808 (15.08%)	4951 (15.83%)		0.021
≥800 (n, %)	4293 (35.81%)	14449 (46.20%)		0.212
CCI (mean, SD)	1.23 (1.99)	1.03 (2.05)	<0.001	0.099
COPD (n, %)	1637 (13.65%)	2689 (8.6%)	<0.001	0.161
Chronic Kidney Disease (n, %)	174 (1.45%)	300 (0.96%)	<0.001	0.045
Diabetes Mellitus (n, %)	1763 (14.71%)	2870 (9.18%)	<0.001	0.017
Coronary Artery Disease (n, %)	39 (0.33%)	50 (0.16%)	0.001	0.34
Myocardial Infarction (n, %)	122 (1.02%)	214 (0.68%)	0.001	0.036
Arterial Hypertension (n, %)	1604 (13.38%)	3034 (9.7%)	<0.001	0.115
Metastatic Cancer (n, %)	505 (4.21%)	1845 (5.9%)	<0.001	0.077
Care setting			<0.001	
Inpatient (n, %)	11138 (92.9%)	28604 (91.45%)		0.054
Outpatient (n, %)	851 (7.1%)	2674 (8.55%)		0.054
Hospital Scale (Beds)			<0.001	
<200 (n, %)	509 (4.25%)	1912 (6.11%)		0.084
200~499 (n, %)	6334 (52.83%)	18078 (57.8%)		0.100
≥500 (n, %)	5146 (42.92%)	11288 (36.09%)		0.140

ASMD: absolute standardized mean difference; SD: standard deviation; BMI: body mass index; CCI: Charlson comorbidity index; COPD: Chronic Obstruction Pulmonary Disease.

\*Small Nodule: T1a and T2b stage patients according to the eighth edition TNM stage classification for lung cancer.

†The Japan Society for the Study of Obesity (JASSO) defines BMI classifications as follows: underweight, <18.5 kg/m2; normal, 18.5 to <25 kg/m2; obese, ≥25 kg/m2.

- Among SN patients who received biopsies, 37.7% had multiple biopsies and was higher than LN patients (29.2%, p < .001). SN patients experienced longer time to cancer confirmation: 90 days longer from first procedure to confirmation, and 45 days longer from first suspected diagnosis to confirmation (p < 0.001).

Table2. Procedures before lung cancer confirmation

Characteristics	Small Nodule* (n = 11989)	T1c-T4 (n = 31278)	p-value
Received Biopsy (n, %)	2423 (20.2%)	6482 (20.7%)	0.242
Multiple (n, %)	913 (37.7%)	1891 (29.2%)	<0.001
Single (n, %)	1510 (62.3%)	4591 (70.8%)	
Average Biopsy numbers including 0 (mean, SD)	0.29 (0.63)	0.28 (0.60)	0.154
Average Biopsy numbers excluding 0 (mean, SD)	1.42 (0.60)	1.34 (0.58)	<0.001
Average Biopsy numbers excluding 0&1 (mean, SD)	2.10 (0.43)	2.15 (0.48)	0.012
First Biopsy Type			<0.001
EBUS-TBNA (n, %)	223 (9.2%)	787 (12.1%)	
TB Cryobiopsy (n, %)	10 (0.4%)	39 (0.6%)	
TB Navigation (n, %)	56 (2.3%)	117 (1.8%)	
TB Virtual Broncoscpoe (n, %)	69 (2.8%)	117 (1.8%)	
TBLB (n, %)	1742 (71.9%)	4636 (71.5%)	
TTNA (n, %)	323 (13.3%)	786 (12.1%)	
Received imaging (n, %)	11971 (99.8%)	31162 (99.6%)	<0.001
Received imaging number (mean, SD)	8.09 (9.96)	6.29 (9.29)	<0.001
First Procedure Type			<0.001
Biopsy (n, %)	147 (1.2%)	664 (2.1%)	
Imaging (n, %)	11842 (98.8%)	30614 (97.9%)	
Days from 1 <sup>st</sup> Procedure to lung cancer confirmation (mean, SD)	498.83 (785.28)	409.91 (778.53)	<0.001
Days from 1 <sup>st</sup> Biopsy to lung cancer confirmation (mean, SD)	85.38 (248.23)	52.16 (219.46)	<0.001
Days from 1 <sup>st</sup> Imaging to lung cancer confirmation (mean, SD)	499.54 (785.66)	411.16 (789.39)	<0.001
Days from lung cancer suspected to confirmation (mean, SD)	197.76 (441.10)	152.93 (440.66)	<0.001

EBUS-TBNA: endobronchial ultrasound transbronchial needle aspiration; TB: tuberculous; TBLB: transbronchial lung biopsy; TTNA: transthoracic needle aspiration

\*Small Nodule: T1a and T2b stage patients according to the eighth edition TNM stage classification for lung cancer.




Figure 1. Forest Plot of Multivariate Logistic Regression in Lung Cancer Patients

- Biopsy before cancer confirmation was more common in patients with smaller nodules, but rare in SN patients with T1a or T1b tumors (< 2 cm). Factors associated with a higher likelihood of pre-diagnosis biopsy included younger age, obesity, smoking, larger hospital size, frequent imaging, COPD, hypertension, diabetes, and metastatic disease.

## CONCLUSIONS

- This study highlights the diagnostic challenges of SN lung cancer in Japan and identifies factors for early diagnosis. Addressing low biopsy rates and improving biopsy technology may enhance early detection and patient outcomes.